Analyst initiations: WL, DRH and OMRI

Filed under: Analyst reports, Analyst initiations

MOST NOTEWORTHY:

• B. Riley initiated Wilmington Trust (NYSE: WL) with a Neutral rating and $33 target and points out the company has greater exposure to construction and development loans than most small- and mid-cap banks.
  


• DiamondRock Hospitality (NYSE: DRH) was assumed with a Market perform rating and $13.50 target at Keefe Bruyette. The firm sees limited upside given expectations for continued moderation in RevPAR trends, limited operating margin expansion and an uncertain economic outlook.
  


• Rodman & Renshaw believes that the issues that have plagued Omrix Biopharm (NASDAQ: OMRI) are now largely reflected in shares and that the company has improved visibility on business fundamentals with solid execution. The firm assumed coverage with an Outperform rating and $18 target.

• UBS initiated Millennium Pharma (NASDAQ: MLNM) with a Neutral rating and $16 target.
  


• Credit Suisse initiated Ryanair (NASDAQ: RYAAY) with a Neutral rating.
  


• Morgan Stanley started Brasken (NYSE: BAK) with an Underweight rating.

<map name="google_ad_map_145-1153505"><area href="http://imageads.googleadservices.com/pagead/imgclick/145-1153505?pos=0" shape="rect" coords="1,2,367,28" /><area href="http://services.google.com/feedback/abg" shape="rect" coords="384,10,453,23" /></map>